FAQs: Luxturna (voretigene neparvovec)
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Search results
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.
Genetic testing, usually via a blood sample, is used to try and identify which gene contains the fault that is causing an individual’s sight loss.
Different inherited sight loss conditions present noticeable symptoms at different times.
Our community are the reason we are able to continue supporting those with inherited sight-loss conditions through research and practical support.
We have created Discover Wellbeing to help people affected by inherited sight loss to develop an awareness of emotional wellbeing and the practical skills to adapt to life’s ups and downs.
Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.
Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.
Giving a regular monthly or quarterly donation of any amount is a wonderful way to help Retina UK support the inherited sight loss community.
Tickle everyone’s taste buds and help raise funds for Retina UK with our Great Bake fundraiser!
Be a souper-star and raise funds whilst having lunch for #TeamRetinaUK